Interferon alpha in systemic lupus erythematosus
- PMID:20652065
- PMCID: PMC2896914
- DOI: 10.1155/2010/948364
Interferon alpha in systemic lupus erythematosus
Abstract
The pleiotropic cytokine interferon alpha is involved in multiple aspects of lupus etiology and pathogenesis. Interferon alpha is important under normal circumstances for antiviral responses and immune activation. However, heightened levels of serum interferon alpha and expression of interferon response genes are common in lupus patients. Lupus-associated autoantibodies can drive the production of interferon alpha and heightened levels of interferon interfere with immune regulation. Several genes in the pathways leading to interferon production or signaling are associated with risk for lupus. Clinical and cellular manifestations of excess interferon alpha in lupus combined with the genetic risk factors associated with interferon make this cytokine a rare bridge between genetic risk and phenotypic effects. Interferon alpha influences the clinical picture of lupus and may represent a therapeutic target. This paper provides an overview of the cellular, genetic, and clinical aspects of interferon alpha in lupus.
Figures


Similar articles
- Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha.Lichtman EI, Helfgott SM, Kriegel MA.Lichtman EI, et al.Clin Immunol. 2012 Jun;143(3):210-21. doi: 10.1016/j.clim.2012.03.005. Epub 2012 Apr 6.Clin Immunol. 2012.PMID:22525889Free PMC article.Review.
- Characterization of Type-I IFN subtype autoantibodies and activity in SLE serum and urine.Harris BD, Kuruganti S, Deshpande A, Goepfert PA, Chatham WW, Walter MR.Harris BD, et al.Lupus. 2020 Aug;29(9):1095-1105. doi: 10.1177/0961203320935976. Epub 2020 Jul 1.Lupus. 2020.PMID:32611267Free PMC article.
- Interferon-alpha: a therapeutic target in systemic lupus erythematosus.Crow MK.Crow MK.Rheum Dis Clin North Am. 2010 Feb;36(1):173-86, x. doi: 10.1016/j.rdc.2009.12.008.Rheum Dis Clin North Am. 2010.PMID:20202598Free PMC article.
- The central role of dendritic cells and interferon-alpha in SLE.Pascual V, Banchereau J, Palucka AK.Pascual V, et al.Curr Opin Rheumatol. 2003 Sep;15(5):548-56. doi: 10.1097/00002281-200309000-00005.Curr Opin Rheumatol. 2003.PMID:12960479Review.
- The immunopathology of cutaneous lupus erythematosus.Kirchhof MG, Dutz JP.Kirchhof MG, et al.Rheum Dis Clin North Am. 2014 Aug;40(3):455-74, viii. doi: 10.1016/j.rdc.2014.04.006.Rheum Dis Clin North Am. 2014.PMID:25034156Review.
Cited by
- Artesunate inhibits type I interferon-induced production of macrophage migration inhibitory factor in patients with systemic lupus erythematosus.Feng X, Chen W, Xiao L, Gu F, Huang J, Tsao BP, Sun L.Feng X, et al.Lupus. 2017 Jan;26(1):62-72. doi: 10.1177/0961203316651738. Epub 2016 May 26.Lupus. 2017.PMID:27230555Free PMC article.
- Activation of the Interferon Pathway is Dependent Upon Autoantibodies in African-American SLE Patients, but Not in European-American SLE Patients.Ko K, Koldobskaya Y, Rosenzweig E, Niewold TB.Ko K, et al.Front Immunol. 2013 Oct 1;4:309. doi: 10.3389/fimmu.2013.00309. eCollection 2013.Front Immunol. 2013.PMID:24101921Free PMC article.
- Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha.Lichtman EI, Helfgott SM, Kriegel MA.Lichtman EI, et al.Clin Immunol. 2012 Jun;143(3):210-21. doi: 10.1016/j.clim.2012.03.005. Epub 2012 Apr 6.Clin Immunol. 2012.PMID:22525889Free PMC article.Review.
- Activation and regulation of interferon-β in immune responses.Sin WX, Li P, Yeong JP, Chin KC.Sin WX, et al.Immunol Res. 2012 Sep;53(1-3):25-40. doi: 10.1007/s12026-012-8293-7.Immunol Res. 2012.PMID:22411096Review.
- GWAS implicates a role for quantitative immune traits and threshold effects in risk for human autoimmune disorders.Gregersen PK, Diamond B, Plenge RM.Gregersen PK, et al.Curr Opin Immunol. 2012 Oct;24(5):538-43. doi: 10.1016/j.coi.2012.09.003. Epub 2012 Sep 28.Curr Opin Immunol. 2012.PMID:23026397Free PMC article.Review.
References
- Ito T, Wang Y-H, Liu Y-J. Plasmacytoid dendritic cell precursors/type I interferon-producing cells sense viral infection by Toll-like receptor (TLR) 7 and TLR9. Springer Seminars in Immunopathology. 2005;26(3):221–229. - PubMed
- Lövgren T, Eloranta M-L, Kastner B, Wahren-Herlenius M, Alm GV, Rönnblom L. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjogren’s syndrome autoantigen-associated RNA. Arthritis and Rheumatism. 2006;54(6):1917–1927. - PubMed
- Schoenemeyer A, Barnes BJ, Mancl ME, et al. The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. Journal of Biological Chemistry. 2005;280(17):17005–17012. - PubMed
- Hoshino K, Sugiyama T, Matsumoto M, et al. IκB kinase-α is critical for interferon-α production induced by Toll-like receptors 7 and 9. Nature. 2006;440(7086):949–953. - PubMed
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical